Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 20 of 47

Summary of Benefits: Dementia

Atypical antipsychotics, as a class, improve behavioral symptoms of dementia, although effect sizes are small in magnitude. This conclusion is supported with high strength of evidence.

When examined individually, some, but not all, atypical antipsychotics demonstrate statistically significant differences from placebo for some outcomes. Aripiprazole and olanzapine improve scores on agitation subscales but not psychosis scores. The evidence for aripiprazole is low strength and for olanzapine it is moderate strength. Risperidone is superior to placebo on both agitation and psychosis subscales, a conclusion supported by high strength of evidence. The evidence for quetiapine is mixed and insufficient to permit conclusions.